8-KOther Events

Edwards Lifesciences Corp 8-K Report (Sep 15, 2000)

Filed September 15, 2000For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) filed an 8-K on September 14, 2000, reporting the completion of a significant asset divestiture. On August 31, 2000, the company sold most assets related to its Bentley line of cardiopulmonary (perfusion) products to Jostra AG affiliates for approximately $30 million in cash. This strategic move involves products used to support the heart during cardiac surgery, including oxygenators, blood reservoirs, and filters. The filing also includes unaudited pro forma financial information, presenting the financial impact of this sale as if it had occurred earlier. Investors should note the substantial pre-tax impairment charge of $291 million recorded in the second quarter of 2000, primarily related to goodwill, to write down the assets to their fair value based on the sale proceeds. This divestiture suggests a strategic shift for Edwards Lifesciences, focusing on other areas of its business.

Key Highlights

  • 1Edwards Lifesciences divested its Bentley line of cardiopulmonary (perfusion) products on August 31, 2000.
  • 2The sale generated approximately $30 million in cash proceeds.
  • 3The buyer of the assets was Jostra AG, a German corporation, through its affiliates.
  • 4The divested products include oxygenators, blood reservoirs, and filters used in cardiac surgery.
  • 5A significant pre-tax impairment charge of $291 million was recognized in Q2 2000, primarily impacting goodwill, to adjust asset carrying values to fair value.
  • 6Unaudited pro forma financial statements are provided to illustrate the financial impact of the divestiture.
  • 7The divestiture represents a strategic move to streamline the company's product portfolio.

Frequently Asked Questions

Edwards Lifesciences sold most of the assets associated with its Bentley line of cardiopulmonary products, also referred to as 'perfusion products.' These are products used to support the heart during cardiac surgery.

The company received approximately $30 million in cash proceeds from the sale of the Bentley product line.

Edwards Lifesciences recorded a pre-tax impairment charge of $291 million primarily related to goodwill. This charge was taken to reduce the carrying value of the assets being sold to their estimated fair value, based on the net proceeds expected from the sale, in accordance with accounting standards for assets to be disposed of.

The unaudited pro forma financial information shows how the company's financial statements would have looked if the sale of the Bentley product line had occurred on an earlier date. This helps investors understand the ongoing financial performance of the company without the divested business.